What: DURECT Corporation's First Quarter 2002 Earnings Conference Call When: Wednesday, April 24th, 2002, 4:30 p.m. EDT Where: www.durect.com and click "Investor Relations" How: Live over the Internet -- Simply log on to the Web at the address listed above. Contact: Suzanne Watson, DURECT Corporation, 408-864-7489, firstname.lastname@example.orgIf you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. DURECT's lead product in development, the CHRONOGESIC(TM) (sufentanil) Pain Therapy System, a 3-month product for the treatment of chronic pain, completed a pilot phase III study in December 2001. DURECT owns three proprietary drug delivery platform technologies, including the SABER(TM) Delivery System (a patented and versatile depot injectable useful for protein delivery), the MICRODUR(TM) Biodegradable Microparticulates (microspheres injectable system) and the DURIN(TM) Biodegradable Implant (drug-loaded implant system).
CHRONOGESIC(TM)is a trademark of DURECT Corporation. SABER(TM), MICRODUR(TM)and DURIN(TM)are trademarks of Southern BioSystems, Inc., a wholly owned subsidiary of DURECT Corporation.
The statements in this press release regarding DURECT's products in development, expected product benefits, product development plans, future clinical trials or potential product markets are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, DURECT's ability to research, develop, manufacture and commercialize its products, obtain product and manufacturing approvals from regulatory agencies, manage its growth and expenses, finance its activities and operations, as well as marketplace acceptance of DURECT's products. Further information regarding these and other risks is included in DURECT's Annual Report on Form 10-K for the fiscal year ended December 31, 2001 filed with the SEC on March 28, 2002, under the heading "Factors that may affect future results," and other periodic reports filed with the SEC. CHRONOGESIC is under development by DURECT and has not been submitted or approved for commercialization by the US Food and Drug Administration or other health authorities.
CONTACT: DURECT Corporation Schond L. Greenway, 408/777-1417 email@example.com URL: http://www.businesswire.com Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page.
Copyright (C) 2002 Business Wire. All rights reserved.